Clinical Trials

Status
Published

1558 Results

Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer

Status Notes
Activation Date: 06/06/2022
Research Committee(s)
Gastrointestinal Cancer
Activated
06-06-2022
ClinicalTrials.gov Registry Number
NCT05308446
Open
Accrual
5%
SWOG Clinical Trial Number
S1800D

A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

Status Notes
S1800D will open to accrual February 15, 2022, effective 12:00 pm PST. This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
02-15-2022
Open
Phase
II-III
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Status Notes
This study is open to accrual on December 21, 2021.
Research Committee(s)
Lung Cancer
Activated
12-21-2021
Open
Phase
II-III
Accrual
0%
SWOG Clinical Trial Number
S2012

Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)

Status Notes
Activation: Effective December 02, 2021 at 2:00 p.m. Eastern.
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12-02-2021
ClinicalTrials.gov Registry Number
NCT05058651
Open
Phase
III
Accrual
0%
SWOG Clinical Trial Number
S2011

Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery For Cisplatin-Ineligible Muscle-Ineligible Urothelial Carcinoma: SWOG GAP TRIAL

Status Notes
The study referenced above is open for participant accrual effective October 6th, 2021, at 12:00 p.m. Eastern Time.
Research Committee(s)
Genitourinary Cancer
Activated
10-06-2021
ClinicalTrials.gov Registry Number
04871529
Open
Accrual
0%
SWOG Clinical Trial Number
S1934

NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer

Status Notes
S1934 will reactivate 02/15/2022.
Research Committee(s)
Lung Cancer
Activated
09-09-2021
ClinicalTrials.gov Registry Number
04989283
Open
Phase
II
Accrual
14%
SWOG Clinical Trial Number
S2013

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Status Notes
S2013 will open to accrual on August 16, 2021, effective 12:00 pm PST.
Research Committee(s)
Symptom Control and Quality of Life
Activated
08-16-2021
Open
Accrual
5%
SWOG Clinical Trial Number
S1912CD

A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)

Status Notes
All protocol documents will be accessible from the S1912CD protocol abstract page on www.ctsu.org (login required).
Research Committee(s)
Cancer Care Delivery
Activated
07-26-2021
ClinicalTrials.gov Registry Number
NCT 04960787
Open
Phase
Accrual
53%
SWOG Clinical Trial Number
CTSU/EAA173
Research Committee(s)
Cancer Care Delivery
Head and Neck Cancer
Activated
07-02-2021
ClinicalTrials.gov Registry Number
bitospitokulaslijuprabroreuudrigaprusteslichadigamostepipuwricrusuclonupostohukidewrephutheceswadra
Open
Phase
Accrual
2%
SWOG Clinical Trial Number
S2005

A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoclax in Previously Untreated Waldenstrom's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)

Status Notes
Re-Activation – Effective (9/20/2021)
Research Committee(s)
Myeloma
Activated
06-24-2021
ClinicalTrials.gov Registry Number
04840602
Open
Phase
III
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer

Status Notes
CTSU/NRG-BR007 has been endorsed and activated by SWOG, effective 6/15/2021. CTSU/NRG-BR007 was activated by NRG Oncology, effective 6/7/21.
Research Committee(s)
Breast Cancer
Activated
06-07-2021
ClinicalTrials.gov Registry Number
04852887
Open
Phase
SWOG Clinical Trial Number
CTSU/ANHL1931

A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.

Status Notes
CTSU/ANHL1931 was temporarily closed to accrual on 6/24/21.
CTSU/ANHL1931 has been endorsed and activated by SWOG, effective 7/15/21. CTSU/ANHL1931 was activated by Children's Oncology Group, effective 6/7/21.
Research Committee(s)
Lymphoma
Activated
06-07-2021
ClinicalTrials.gov Registry Number
04759586
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA2201

A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

Status Notes
May Thet Cho, MD SWOG Champion
Research Committee(s)
Gastrointestinal Cancer
Activated
05-13-2021
ClinicalTrials.gov Registry Number
NCT04751370
Open
Phase
III
SWOG Clinical Trial Number
CTSU/A031901

Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial

Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Research Committee(s)
Genitourinary Cancer
Activated
05-01-2021
ClinicalTrials.gov Registry Number
NCT04637594
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA8185

Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)

Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Research Committee(s)
Genitourinary Cancer
Activated
05-01-2021
ClinicalTrials.gov Registry Number
NCT04216290
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA2192
Open
Phase
II
Accrual
55%
SWOG Clinical Trial Number
S1900E

A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Status Notes
S1900E will open to accrual April 2, 2021, effective 12:00 pm PST.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
04-02-2021
Open
Phase
II-III
Accrual
8%
SWOG Clinical Trial Number
S1918

A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

Status Notes
Activation - Effective 3/19/21, 12:00 pm Pacific Time

Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.

Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.

Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
Research Committee(s)
Lymphoma
Activated
03-19-2021
ClinicalTrials.gov Registry Number
04799275
Open
Phase
III
Accrual
2%
SWOG Clinical Trial Number
S1937

A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.

Status Notes
This study is open to accrual effective February 16, 2021.
Research Committee(s)
Genitourinary Cancer
Activated
02-16-2021
ClinicalTrials.gov Registry Number
NCT04579224
Open
Phase
III